These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21714657)

  • 21. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
    Vogelmeier C; Hederer B; Glaab T; Schmidt H; Rutten-van Mölken MP; Beeh KM; Rabe KF; Fabbri LM;
    N Engl J Med; 2011 Mar; 364(12):1093-1103. PubMed ID: 21428765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cost-effectiveness analysis of tiotropium compared to ipratropium and salmeterol].
    García Ruiz AJ; Leiva Fernández F; Martos Crespo F
    Arch Bronconeumol; 2005 May; 41(5):242-8. PubMed ID: 15919004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®).
    Vogelmeier CF; Asijee GM; Kupas K; Beeh KM
    Adv Ther; 2015 Jun; 32(6):537-47. PubMed ID: 26100349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
    Bateman ED; van Dyk M; Sagriotis A
    Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The INSPIRE trial results: are they truly breathtaking?
    Chui D; Tejani AM
    Am J Respir Crit Care Med; 2009 Jan; 179(1):80; author reply 80-1. PubMed ID: 19098157
    [No Abstract]   [Full Text] [Related]  

  • 26. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD.
    Briggs DD; Covelli H; Lapidus R; Bhattycharya S; Kesten S; Cassino C
    Pulm Pharmacol Ther; 2005; 18(6):397-404. PubMed ID: 16179215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
    Fabbri LM; Calverley PM; Izquierdo-Alonso JL; Bundschuh DS; Brose M; Martinez FJ; Rabe KF;
    Lancet; 2009 Aug; 374(9691):695-703. PubMed ID: 19716961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis.
    Van den Bruel A; Gailly J; Neyt M
    BMC Pulm Med; 2010 Sep; 10():50. PubMed ID: 20858226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.
    Cazzola M; Andò F; Santus P; Ruggeri P; Di Marco F; Sanduzzi A; D'Amato M
    Pulm Pharmacol Ther; 2007; 20(5):556-61. PubMed ID: 16914336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naïve patients.
    Vogelmeier C; Fabbri LM; Rabe KF; Beeh KM; Schmidt H; Metzdorf N; Glaab T
    Respir Med; 2013 Jan; 107(1):75-83. PubMed ID: 23102611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Debates surrounding COPD].
    Tillie-Leblond I; Housset B
    Rev Mal Respir; 2010 Feb; 27(2):106-7. PubMed ID: 20206057
    [No Abstract]   [Full Text] [Related]  

  • 32. Chronic obstructive pulmonary disease megatrials: taking the results into office practice.
    Stoloff SW
    Am J Med Sci; 2011 Aug; 342(2):160-7. PubMed ID: 21512392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.
    Rabe KF; Timmer W; Sagkriotis A; Viel K
    Chest; 2008 Aug; 134(2):255-262. PubMed ID: 18403672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tiotropium: a new therapeutic option in asthma.
    Novelli F; Costa F; Latorre M; Malagrinò L; Celi A; Vagaggini B; Paggiaro P
    Monaldi Arch Chest Dis; 2013; 79(3-4):109-15. PubMed ID: 24761528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Short-term effect of tiotropium in COPD patients being treated with a beta2 agonist].
    Fernandes FL; Pavezi VA; Dias SA; Pinto RM; Stelmach R; Cukier A
    J Bras Pneumol; 2010; 36(2):181-9. PubMed ID: 20485938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease.
    Hoshino M; Ohtawa J
    Respirology; 2011 Jan; 16(1):95-101. PubMed ID: 20920142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of tiotropium or combined therapy with salmeterol on hyperinflation in COPD.
    Eguchi Y; Tateishi Y; Umeda N; Yoshikawa T; Kamoi H; Kanazawa H; Kudoh S; Hirata K; Fujimoto S
    Osaka City Med J; 2007 Jun; 53(1):25-34. PubMed ID: 17867631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of bronchodilators on regional lung sound distribution in patients with chronic obstructive pulmonary disease.
    Mineshita M; Matsuoka S; Miyazawa T
    Respiration; 2014; 87(1):45-53. PubMed ID: 23860295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prevention in chronic obstructive pulmonary disease. POET-COPD (prevention of exacerbations with tiotropium in COPD)].
    Gillissen A; Nitschmann S
    Internist (Berl); 2011 Dec; 52(12):1492-4. PubMed ID: 22033914
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD.
    Bateman ED; Kornmann O; Ambery C; Norris V
    Pulm Pharmacol Ther; 2013 Oct; 26(5):581-7. PubMed ID: 23538170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.